

SEEING THE WORLD BETTER

Procedures for Requesting or Viewing Proxy Information for the Combined (Ordinary and Extraordinary) Annual Meeting on May 11, 2017

Charenton-le-Pont, France (April 7, 2017 – 8:00 p.m. CEST) – Shareholders are advised that the Combined (Ordinary and Extraordinary) Annual Meeting will be held on **Thursday, May 11, 2017 at 10:45 a.m. CEST** at the **Maison de la Mutualité** – 24, rue Saint-Victor – 75005 Paris – France.

The preliminary notice of meeting, published in the *Bulletin des Annonces Légales Obligatoires* on March 29, 2017, contains information on the agenda, the proposed resolutions and the procedures for attending and voting.

Proxy information may be viewed in the Investors section of the Essilor corporate website at <u>www.essilor.com</u>: "Annual Shareholders' Meetings".

As provided for in Articles R.225-88 and R.225-89 of the French Commercial Code, any shareholder may consult the proxy documents and information, as described in Article R.225-83 of the French Commercial Code, at Company headquarters (147 rue de Paris – 94220 Charenton-le-Pont – France) or request that such documents be sent to him or her, by writing to:

Société Générale – Service des Assemblées – CS 30812 – 44308 Nantes Cedex 03 – France.

About Essilor

The world's leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than \in 200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux[®], Crizal[®], Transitions[®], EyezenTM, Xperio[®], Foster Grant[®], BolonTM and Costa[®]. It also develops and markets equipment, instruments and services for eyecare professionals. Essilor reported consolidated revenue of more than \in 7.1 billion in 2016 and employs 64,000 people worldwide. It markets its products in more than 100 countries and has 33 plants, 490 prescription laboratories and edging facilities, as well as 5 research and development centers around the world. For more information, please visit www.essilor.com. The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

Investor Relations and Financial Communications Phone: +33 (0)1 49 77 42 16